TRNS Stock Analysis: Transcat | NASDAQ

Calibration, Test Instruments, Measurement Instruments, Asset Management

Total Rating 57

Safety 85

Buy Signal -0.14

Specialty Business Services
Industry Rotation: -3.7

Market Cap: 839M
Avg Turnover: 11.5M

Risk 3d forecast

Volatility44.8%

VaR 5^th Pctl7.33%

VaR vs Median-0.52%

Reward TTM

Sharpe Ratio0.30

Rel. Str. IBD72.9

Rel. Str. Peer Group74.2

Character TTM

Beta0.792

Beta Downside0.437

Hurst Exponent0.583

Drawdowns 3y

Max DD63.86%

CAGR/Max DD-0.07

CAGR/Mean DD-0.13

EPS (Earnings per Share)

EPS CAGR: -6.01%
EPS Trend: -43.6%

Last SUE: 1.44
Qual. Beats: 1

Revenue

Rev. CAGR: 13.26%
Rev. Trend: 98.4%

Last SUE: 2.16
Qual. Beats: 1

Warnings

P/E Ratio 242.3

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 11.6 years of data

Jan +1.1% 5

Feb -0.9% 15

Mar -1.3% 20

Apr -1.2% 8

May +5.6% 24

Jun -0.3% 10

Jul +1.8% 2

Aug +4.0% 54

Sep -1.6% 31

Oct -2.0% 14

Nov +1.6% 23

Dec +0.1% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TRNS Transcat

Transcat, Inc. (NASDAQ: TRNS) is a provider of calibration and laboratory instrument services operating in the United States, Canada, and internationally. Founded in 1964 and headquartered in Rochester, New York, the company is classified within the Industrials sector under the Trading Companies & Distributors sub-industry, and trades as a small-cap stock with a market capitalization of approximately $861 million. The company has been publicly listed since 1990.

The business operates through two segments: Service and Distribution. The Service segment delivers calibration, repair, inspection, analytical qualification, preventative maintenance, and consulting services. It is supported by CalTrak, a proprietary document and asset management system for calibration workflows, and an online Compliance, Control, and Cost customer portal for managing service records.

The Distribution segment sells and rents test, measurement, and control instruments, complemented by value-added services such as equipment calibration, rental, used equipment sales, and kitting. Marketing channels include the company website, digital and print advertising, outbound sales, and an inbound call center.

Transcat serves highly regulated industries, principally life sciences (pharmaceuticals, biotechnology, medical devices, and other FDA-regulated sectors), along with aerospace and defense, industrial manufacturing, energy and utilities, oil and gas, and chemical manufacturing, all of which require traceable measurement accuracy for compliance and process control.

Headlines to Watch Out For

Service segment organic growth drives margin expansion
Life sciences demand from FDA-regulated pharma customers accelerates
Acquisitions of regional calibration labs expand service network

Piotroski VR-10 (Strict) 4.0

Net Income: 3.45m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.16 > 1.0
NWC/Revenue: 16.45% < 20% (prev 18.06%; Δ -1.61% < -1%)
CFO/TA 0.08 > 3% & CFO 40.0m > Net Income 3.45m
Net Debt (169.4m) to EBITDA (38.9m): 4.35 < 3
Current Ratio: 2.49 > 1.5 & < 3
Outstanding Shares: last quarter (9.47m) vs 12m ago 2.00% < -2%
Gross Margin: 32.50% > 18% (prev 32.50%; Δ -0.01% > 0.5%)
Asset Turnover: 78.72% > 50% (prev 73.86%; Δ 4.86% > 0%)
Interest Coverage Ratio: 1.97 > 6 (EBIT TTM 11.4m / Interest Expense TTM 5.79m)

Altman Z'' 3.27

A: 0.12 (Total Current Assets 95.7m - Total Current Liabilities 38.4m) / Total Assets 492.6m
B: 0.20 (Retained Earnings 98.8m / Total Assets 492.6m)
C: 0.03 (EBIT TTM 11.4m / Avg Total Assets 442.6m)
D: 1.60 (Book Value of Equity 302.9m / Total Liabilities 189.7m)
Altman-Z'' = 3.27 = A

Beneish M -2.82

DSRI: 0.96 (Receivables 67.5m/58.4m, Revenue 348.4m/289.9m)
GMI: 1.00 (GM 32.50% / 32.50%)
AQI: 1.17 (AQ_t 0.69 / AQ_t-1 0.59)
SGI: 1.20 (Revenue 348.4m / 289.9m)
TATA: -0.07 (NI 3.45m - CFO 40.0m) / TA 492.6m)
Beneish M = -2.82 (Cap -4..+1) = A

What is the price of TRNS shares?

As of August 28, 2026, the stock is trading at USD 89.87 with a total of 103,642 shares traded. Over the past week, the price has changed by -1.79%, over one month by +4.33%, over three months by +11.89% and over the past year by +7.74%.

Current recommended Stop Loss: 80.40 (which is 10.5% or 2.2 ATR below the current price).

Is TRNS a buy, sell or hold?

Transcat has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold TRNS.

StrongBuy: 1
Buy: 1
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TRNS price?

Analysts Target Price	104.3	16.1%

Transcat (TRNS) - Fundamental Data Overview as of 28 August 2026

Market Cap USD = 839.2m (839.2m USD * 1.0 USD.USD)
P/E Trailing = 242.3243
P/E Forward = 50.2513
P/S = 2.4087
P/B = 2.7285
Revenue TTM = 348.4m USD
EBIT TTM = 11.4m USD
EBITDA TTM = 38.9m USD
Long Term Debt = 110.4m USD (from longTermDebt, last quarter)
Short Term Debt = 4.47m USD (from shortTermDebt, last quarter)
Debt = 176.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.9m
Net Debt = 169.4m USD (calculated: Debt 176.1m - CCE 6.71m)
Enterprise Value = 1.01b USD (839.2m + Debt 176.1m - CCE 6.71m)
Interest Coverage Ratio = 1.97 (Ebit TTM 11.4m / Interest Expense TTM 5.79m)
EV/FCF = 39.81x (Enterprise Value 1.01b / FCF TTM 25.3m)
FCF Yield = 2.51% (FCF TTM 25.3m / Enterprise Value 1.01b)
FCF Margin = 7.27% (FCF TTM 25.3m / Revenue TTM 348.4m)
Net Margin = 0.99% (Net Income TTM 3.45m / Revenue TTM 348.4m)
Gross Margin = 32.50% ((Revenue TTM 348.4m - Cost of Revenue TTM 235.2m) / Revenue TTM)
Gross Margin QoQ = 33.07% (prev 34.11%)
Tobins Q-Ratio = 2.05 (Enterprise Value 1.01b / Total Assets 492.6m)
Interest Expense / Debt = 3.29% (Interest Expense 5.79m / Debt 176.1m)
Taxrate = 38.56% (2.16m / 5.61m)
NOPAT = 7.00m (EBIT 11.4m * (1 - 38.56%))
Current Ratio = 2.49 (Total Current Assets 95.7m / Total Current Liabilities 38.4m)
Debt / Equity = 0.58 (Debt 176.1m / totalStockholderEquity, last quarter 302.9m)
Debt / EBITDA = 4.35 (Net Debt 169.4m / EBITDA 38.9m)
Debt / FCF = 6.69 (Net Debt 169.4m / FCF TTM 25.3m)
Total Stockholder Equity = 298.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.78% (Net Income 3.45m / Total Assets 492.6m)
RoE = 1.15% (Net Income TTM 3.45m / Total Stockholder Equity 298.9m)
RoCE = 2.78% (EBIT 11.4m / Capital Employed (Equity 298.9m + L.T.Debt 110.4m))
RoIC = 1.55% (NOPAT 7.00m / Invested Capital 452.0m)
WACC = 7.60% (E(839.2m)/V(1.02b) * Re(8.77%) + D(176.1m)/V(1.02b) * Rd(3.29%) * (1-Tc(0.39)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.94 | Cagr: 4.65%
[DCF] Terminal Value 77.97% ; FCFF base≈23.0m ; Y1≈26.4m ; Y5≈38.8m
[DCF] Fair Price = 44.36 (EV 584.6m - Net Debt 169.4m = Equity 415.2m / Shares 9.36m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -43.61 | EPS CAGR: -6.01% | SUE: 1.44 | # QB: 1
Revenue Correlation: 98.36 | Revenue CAGR: 13.26% | SUE: 2.16 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.45 | Chg30d=+7.19% | Revisions=+29% | Analysts=4
EPS next Quarter (2026-12-31): EPS=0.30 | Chg30d=-8.46% | Revisions=+29% | Analysts=4
EPS current Year (2027-03-31): EPS=1.91 | Chg30d=+8.24% | Revisions=+29% | GrowthEPS=+3.5% | GrowthRev=+12.6%
EPS next Year (2028-03-31): EPS=2.17 | Chg30d=+1.17% | Revisions=+0% | GrowthEPS=+13.8% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: +32% (up=11, down=5)